Palmitoleic acid

Palmitoleic Acid (Omega-7 Monounsaturated Fatty Acid)

1. Identity: Chemical Names, Structure, and Common Forms

Palmitoleic acid, or (9Z)-hexadec-9-enoic acid, is an omega-7 monounsaturated fatty acid (16:1n-7) with the molecular formula CH₃(CH₂)₅CH=CH(CH₂)₇COOH. Its molecular weight is 254.4082 g/mol, its IUPAC name is (Z)-hexadec-9-enoic acid, its CAS registry number is 373-49-9, and its PubChem CID is 445638.

Palmitoleate (16:1n–7 or 16:1Δ9) is a monounsaturated fatty acid (MUFA) with 16 carbons. The double bond is located in the n–7 or Δ9 carbon, counting from the methyl-terminal carbon or the carboxylic acid end, respectively. It belongs to the group of unsaturated fatty acids, having one cis double bond from the methyl end in the omega-7 (ω-7) or n-7 position, and is also a member of the subgroup called long-chain fatty acids (LCFA), which span from 14 to 18 carbon atoms.

Palmitoleic acid exists in two isomers: cis and trans. Its endogenous production by stearoyl-CoA desaturase 1 (SCD1) gives rise to its cis isoform, cis-palmitoleate. Although trans-palmitoleate is also synthesized in humans, it is mainly found as an exogenous source in ruminant fat and dairy products.

Synonyms include C16:1(9Z), C16:1 n-7, FA 16:1, (9Z)-Hexadecenoic Acid, and cis-Palmitoleic Acid.

The monounsaturated fatty acid palmitoleate is one of the most abundant fatty acids in serum and tissues, particularly adipose tissue and liver. It is present in all tissues but is found in higher concentrations in the liver. It is biosynthesized from palmitic acid by the action of the enzyme Stearoyl-CoA desaturase-1.

Interest in this fatty acid arises partly from its lower susceptibility to oxidation compared to polyunsaturated fatty acids, which may confer functional advantages such as stability during frying and baking.

Common Supplement Forms and Preparations

Palmitoleic acid is available as a dietary supplement primarily in forms derived from its principal botanical and marine sources. Supplements are typically derived from plant sources such as macadamia nuts or sea buckthorn berries. They are available in various forms, including softgel capsules, liquid oils, and powders. Highly purified (greater than 90%) free-form palmitoleic acid preparations have also been developed for use in clinical research, as discussed in more detail below.

2. Natural Sources

Dietary sources with high palmitoleate content include salmon, cod liver oil, and macadamia oil (6%, 7%, and 17% or g/100 g total FAs, respectively). Currently, the highest reported concentration of palmitoleate in foods corresponds to the shrub sea buckthorn (Hippophae rhamnoides), which is native to Asia and Europe, and the oil of its pulp contains palmitoleic acid at 32–42%.

Palmitoleic acid occurs naturally in high levels only in sea buckthorn fruit flesh (up to 52% of total fatty acids) and in macadamia nuts (up to 22% of total fatty acids). Avocado oil, macadamia oil (Macadamia integrifolia), and sea buckthorn oil (Hippophae rhamnoides) are botanical sources with high concentrations, containing 7–12%, 17%, and 19–29% palmitoleic acid, respectively.

Palmitoleic acid is found in trace amounts in most foods except for sardine oil, which contains 15% of this acid as a component of triglycerides. Other dietary sources include breast milk, a variety of animal fats, vegetable oils, and marine oils. Other natural sources of palmitoleate include olive oil, chocolate, and eggs.

Food sources that naturally contain palmitoleic acid are limited and include certain blue-green algae, macadamia nuts (3.7 g/oz; 17% of fat content), and sea buckthorn oil. Of all the fatty acid categories, monounsaturated fatty acids (MUFAs) are consumed the most, and second to oleic acid is palmitoleic acid at approximately 1.2 g/day in typical dietary intake.

The most recognized product of sea buckthorn is its fruit oil, composed of seed oil that is rich in essential fatty acids (linoleic and α-linolenic acids) and pulp oil that contains high levels of monounsaturated palmitoleic acid (16:1ω-7).

3. Historical and Traditional Use

Palmitoleic acid (16 carbon atoms) was first noticed in 1854 by Hofstädter P.G. in sperm whale oil and named physetoleic acid. In 1906 Bull H. discovered its molecular composition, at the time when Lewkowitsch gave it its present name. The structure was formally established in 1925 by Armstrong E.F. et al.

The primary vehicle through which palmitoleic acid has been used historically is sea buckthorn (Hippophae rhamnoides). Sea buckthorn-derived products have traditionally been used as food and medicinal ingredients in Eastern countries. Sea buckthorn is a hardy, fruit-producing plant known historically for its medicinal and nutraceutical properties. The most recognized product of sea buckthorn is its fruit oil, and sea buckthorn is fast gaining popularity as a source of functional food and nutraceuticals.

Sea buckthorn is a deciduous splinter shrub plant of the Elaeagnaceae family with yellow or orange berries, widely grown in the central and northern areas of Eurasia, including Russia, China, Mongolia, France, the Netherlands, Finland, Sweden, and Norway. It has traditionally been used for nutritional and medicinal purposes in various countries. The pulp of its berries contains abundant vitamins, minerals, amino acids, and polyphenolic compounds reported to contribute to human health benefits. Oils extracted from the pulp or seed have traditionally been used for treating mucosal disorders such as dermatitis. In addition, dried or fresh leaves are prepared for nutritious herbal tea as they are rich in nutraceutical components.

Macadamia nuts (Macadamia integrifolia), native to Australia, represent a second botanical vehicle of historical dietary significance. Due to its wide public acceptance and being a commonly occurring food, macadamia nuts may serve as an important dietary agent for the delivery of palmitoleic acid to the human body.

4. Key Constituents, Biosynthesis, and Mechanisms of Action

Biosynthesis and Endogenous Metabolism

Palmitoleic acid mainly originates from de novo lipogenesis in humans. During de novo fatty acid synthesis, stearoyl-CoA desaturase-1 (SCD1) forms oleic and palmitoleic acid (C16:1) by catalyzing the formation of a double bond in stearic acid (C18:0) and palmitic acid (C16:0), respectively. Both in plants and animals it is produced de novo by the Δ9 desaturation of palmitic acid.

Biochemically, palmitoleic acid is produced in the liver and adipose tissue, with its synthesis regulated by diet, hormones, and metabolic state.

The Lipokine Concept

Palmitoleate was considered to be a lipokine based on evidence demonstrating its release from adipose tissue and its metabolic effects on distant organs. Palmitoleic acid has been considered a novel lipid hormone "lipokine," since animal studies demonstrated that palmitoleic acid can be released by adipose tissue and affects the metabolism of distant organs, including the liver and skeletal muscle.

Palmitoleate is produced in adipose tissue and exerts its lipokine actions in adipose tissue, the cardiovascular system, the liver, muscle, the pancreas, and other organs. In humans, subcutaneous lower body fat releases significantly more palmitoleate than other fat depots, linking beneficial effects of palmitoleate with fat distribution.

Molecular Mechanisms

The actions of palmitoleic acid tend to oppose those of palmitic acid, which is known to induce ER stress, inflammation, apoptosis of healthy cells, insulin resistance, glucose intolerance, and steatosis in the liver and muscle.

In cellular and animal studies, palmitoleic acid supplementation has been shown to improve overall glucose metabolism and increase whole-body insulin sensitivity via increased muscle and adipose tissue glucose uptake by enhancing GLUT content and AMPK activation. There are indications that monounsaturated palmitoleic acid improves glycemic control and increases glucose transport into skeletal muscle cells, an effect mediated at least in part by upregulation of the activities of glucose transporters GLUT1 and GLUT4.

Supplementation of palmitoleate decreased the phosphorylation of nuclear factor kappa B (NF-κB, p65) and the expression of proinflammatory cytokines. Treatment with palmitoleate markedly attenuated insulin resistance induced by a high-fat diet, increased glucose uptake and incorporation into muscle in vitro, reduced serum levels of AST, decreased hepatic levels of IL-1β and IL-12, reduced the expression of TLR-4, and increased the expression of IL-1Ra, and reduced the phosphorylation of NF-κB (p65) in the liver.

Similar benefits have been reported following AMPK activation, suggesting a convergent mode of action. A comparison of palmitoleic acid's metabolic effects and AMPK activation reveals a multitude of similarities, suggesting that palmitoleic acid could be exerting at least some of its beneficial effects through AMPK activation.

Palmitoleic acid decreases lipogenesis in toxic storage sites such as the liver and muscle, and paradoxically increases lipogenesis in safe storage sites such as adipose tissue.

Palmitoleate, an omega-7 monounsaturated fatty acid, exerts anti-inflammatory properties in response to lipopolysaccharide (LPS)-mediated inflammation. Exposure of bone marrow–derived macrophages (BMDMs) to LPS or TNFα induces a robust increase in the expression of proinflammatory cytokines, and supplementation of palmitoleate inhibited LPS-mediated upregulation of proinflammatory cytokines.

Studies with cell culture and rodent models have suggested that palmitoleic acid enhances whole-body insulin sensitivity, stimulates insulin secretion by β cells, increases hepatic fatty acid oxidation, improves the blood lipid profile, and alters macrophage differentiation.

Fatty Acid Esters of Hydroxy Fatty Acids (FAHFAs)

Two major types of FAHFAs have been identified in healthy human circulation: palmitoleic acid ester of 9-hydroxystearic acid (9-POHSA), and oleic acid ester of 9-hydroxystearic acid (9-OAHSA). Both 9-POHSA and 9-OAHSA had a strong positive correlation with each other and were negatively correlated with fasting blood glucose, S-adenosyl-l-homocysteine (SAH), and trimethylamine N-oxide (TMAO). Moreover, both 9-POHSA and 9-OAHSA exhibited an anti-inflammatory effect by suppressing LPS-stimulated cytokines, including IL-1β and IL-6.

5. Scientific Evidence by Area of Use

5.1 Insulin Sensitivity and Type 2 Diabetes

Preclinical evidence: In a study examining the antidiabetic effect of palmitoleic acid in KK-Ay mice, a spontaneous model for studies of obese type 2 diabetes with low insulin sensitivity, mice were orally administered vehicle, 300 mg/kg of palmitoleic acid, or 300 mg/kg of palmitic acid (C16:0) on a daily basis for 4 weeks. Palmitoleic acid alleviated liver injury, hepatitis, and dyslipidemia in high-fat diet-induced NAFLD mice, improved insulin resistance, downregulated genes and proteins related to fat synthesis, and upregulated genes and proteins linked to lipolysis and fat oxidation.

Human epidemiological evidence: In a prospective cohort of 3,630 US men and women in the Cardiovascular Health Study, plasma phospholipid fatty acids, anthropometric variables, blood lipids, inflammatory markers, and glucose and insulin concentrations were measured between 1992 and 2006 using standardized methods, with the aim of investigating whether circulating cis-palmitoleate is related to lower metabolic risk and the incidence of diabetes. Although its role in obesity development and its contribution to liver or cardiovascular health is not fully clear, decreased incident diabetes is certainly associated with higher palmitoleate concentrations.

Data from 16 prospective studies with 63,682 participants without known diabetes at baseline and 15,180 participants who developed cases of type 2 diabetes over an average of 9 years and up to 20 years of follow-up were analyzed. Trans-palmitoleic acid was measured as a biomarker of dairy fat consumption. This large meta-analysis showed that higher palmitoleic acid levels are associated with a lower risk of developing type 2 diabetes mellitus.

A longitudinal analysis published in Diabetologia (n=1,234) assessed whole-body insulin sensitivity using a hyperinsulinaemic–euglycaemic clamp and oral glucose tolerance testing. That analysis described, for the first time, a cross-sectional positive relationship between palmitoleate and beta cell function in humans, with potential differences between men and women. This finding is consistent with previous studies in pancreatic islets and isolated beta cells, which exhibited increased basal and glucose-stimulated insulin secretion and were protected from apoptosis induced by glucotoxicity or lipotoxicity when exposed to palmitoleate. Despite this evidence, the lack of a significant association between changes in palmitoleate and beta cell function over time warrants cautious interpretation and confirmation by intervention studies.

In general, studies in humans found positive associations between higher trans-16:1n-7 proportion in plasma phospholipids and improved insulin sensitivity or decreased onset of type 2 diabetes mellitus. However, plasma cis-16:1n-7 data are still controversial.

Complexity of interpretation: Human studies report elevated blood levels of palmitoleic acid in people with obesity and metabolic syndrome. These findings might be a reflection of the level or activity of stearoyl-CoA desaturase-1, which synthesizes palmitoleate and is enhanced in liver and adipose tissue of obese patients. This means that elevated circulating palmitoleate in observational studies may be a marker of metabolic disturbance rather than purely a protective signal, and causality cannot be assumed from association studies alone.

Ongoing clinical trial: A double-blind, placebo-controlled clinical trial is testing the hypothesis that palmitoleic acid increases insulin sensitivity and decreases hepatic lipogenesis in overweight and obese adult subjects with pre-diabetes. Importantly, this is described as the first study ever to use pure (>90%) palmitoleic acid with <0.3% palmitic acid, which is noted to mask the beneficial effects of palmitoleic acid.

Overall evidence strength: Preclinical and large observational data are suggestive, but adequately powered and well-designed human intervention trials are lacking. The field is characterized by the same investigator group publishing most of the intervention data, and at least one key RCT has been retracted (see Section 7). The evidence at present is preliminary.

5.2 Trans-Palmitoleate and Cardiovascular / Metabolic Risk

The trans isomer of palmitoleate has been the subject of specific epidemiological investigation because it is derived almost exclusively from dietary sources (dairy and ruminant products), making it a cleaner proxy for dietary intake, unconfounded by the complexity of endogenous synthesis.

Whereas trans-fats from partially hydrogenated oils unfavorably affect cardiovascular risk, trans-palmitoleate is principally derived from naturally-occurring dairy/ruminant trans-fats, consumption of which has not been associated with higher cardiovascular risk.

In the Cardiovascular Health Study cohort of 3,736 adults, whole-fat dairy consumption was most strongly associated with higher trans-palmitoleate levels, and higher trans-palmitoleate levels were associated with slightly lower adiposity and, independently, with higher high-density lipoprotein cholesterol levels (1.9% across quintiles; P = 0.040). Trans-palmitoleic acid was associated with a 62% lower risk of developing new-onset diabetes.

In a subsequent investigation in MESA (Multi-Ethnic Study of Atherosclerosis), dairy consumption is linked to a lower risk of type 2 diabetes, but constituents responsible for this relation are not established. The investigators examined trans-palmitoleate's association with metabolic risk and incident diabetes in a multiethnic US cohort; phospholipid fatty acids and metabolic risk factors were measured in 2000–2002 among 2,617 adults who were white, Black, Hispanic, and Chinese American.

Higher palmitoleic acid levels in humans are correlated with better insulin sensitivity, an improved lipid profile, and a lower incidence of type 2 diabetes and cardiovascular pathologies such as myocardial infarction.

Overall evidence strength: The trans-palmitoleate findings from the Cardiovascular Health Study and MESA are notable for their size and prospective design, and the association with reduced diabetes risk is consistent. However, these remain observational studies, and the association requires validation in controlled feeding and intervention trials before causal conclusions can be drawn.

5.3 Lipid Profile and Inflammation

Supplementation with palmitoleate or enriched diets shows decreased plasma cholesterol and plasma triglyceride concentrations. When dyslipidemic subjects received capsules with 220.5 mg cis-palmitoleate for 30 days, there were significant reductions in C-reactive protein, triglycerides, and LDL cholesterol and a significant increase in HDL cholesterol. However, this particular study — the Bernstein and Roizen trial — was subsequently retracted from the Journal of Clinical Lipidology due to data reliability concerns (see Section 7).

A more recent, independent double-blind randomized study (n=123) investigated the effect of 500 mg/day or 1,000 mg/day of marine-source palmitoleic acid versus placebo over 12 weeks. The randomized double-blinded parallel arm trial enrolled 123 participants with hs-CRP concentrations of 2 mg/L or higher who consumed 500 mg/day or 1,000 mg/day of marine-source palmitoleic acid or placebo for 12 weeks. Compared to placebo, supplementation for 12 weeks with 500 or 1,000 mg/day did not significantly lower hs-CRP or change other biomarkers.

In various studies, the consumption of macadamia nuts (which contain high cis-palmitoleate concentrations) was related to favorable serum lipid profiles, but not in all studies. Overall, contrasting results in humans could be due to heterogeneous populations, which include healthy subjects and patients with pre-existing dyslipidemia.

Overall evidence strength: The only published purified human RCT has been retracted due to data integrity concerns. The more recent 12-week RCT (n=123) found no significant effect of 500 or 1,000 mg/day on hs-CRP. Evidence from macadamia nut dietary trials is mixed. The lipid and anti-inflammatory benefits seen in preclinical studies have not been consistently replicated in human supplementation trials.

5.4 Non-Alcoholic Fatty Liver Disease (NAFLD)

Animal studies have examined the effects of palmitoleate on liver metabolic and inflammatory responses. Supplementation of palmitoleate decreased the phosphorylation of NF-κB (p65) and the expression of proinflammatory cytokines. These results suggest that palmitoleate acts through dissociating liver inflammatory response from hepatic steatosis to play a unique role in NAFLD.

The anti-inflammatory effects of palmitoleic acid in the liver were accompanied by a reduction in liver macrophages in murine models. Studies using high-fat diet-fed mice with selective deletion of PPAR-γ in myeloid cells showed that palmitoleic acid-mediated improvement of insulin tolerance was tightly dependent on myeloid PPAR-γ, while palmitoleic acid's anti-inflammatory actions including the reduction in liver inflammatory cytokines were preserved in mice bearing myeloid cells deficient in PPAR-γ.

In a 16-week mouse study, palmitoleic acid alleviated liver injury, hepatitis, and dyslipidemia in high-fat diet-induced NAFLD mice. It improved insulin resistance, downregulated genes and proteins related to fat synthesis, and upregulated genes and proteins linked to lipolysis and fat oxidation.

Overall evidence strength: All current NAFLD evidence derives from animal models and cell culture. No controlled human trials have specifically evaluated palmitoleic acid in NAFLD/MASLD patients. Evidence is preclinical only.

5.5 Pancreatic Beta-Cell Function

Adult rat islets exposed to palmitoleic acid (C16:1) alone and in combination with palmitic acid demonstrated that whereas palmitoleic acid stimulates cell proliferation at normoglycemic glucose concentrations, palmitic acid exhibits an inhibitory effect independent of medium glucose level. The monounsaturated palmitoleic acid does not affect cell apoptosis but promotes cell proliferation at low glucose concentrations, counteracting the negative effects of palmitic acid.

Palmitoleic acid supplementation improved beta-cell function and prevented palmitic acid-induced beta-cell death in preclinical models.

Overall evidence strength: Evidence for beta-cell protection and function is based on cell culture (human islets, rat islets) and animal models. Human clinical studies specifically targeting beta-cell preservation are lacking. The longitudinal human association data (from the Diabetologia study) are suggestive but limited by their observational design.

5.6 Dry Eye and Lacrimal Function

Orally administered sea buckthorn pulp oil (not seed oil) restored aqueous tear secretion to its normal value under a dry eye condition in a murine model. Palmitoleate (C16:1), a fatty acid present in sea buckthorn pulp oil, preserved tear secretion and suppressed inflammatory cytokines in the lacrimal gland to the same extent as the pulp oil. These results suggest that oral intake of sea buckthorn pulp oil has a potency to preserve tear secretion capacity in the dry eye state and that palmitoleate, its main constituent fatty acid, is an active component of the oil.

Overall evidence strength: Evidence here is limited to a murine dry-eye model. Controlled human data attributing the effect specifically to the palmitoleate component of sea buckthorn are not yet established.

5.7 Skin and Topical Applications

Palmitoleic acid is naturally present in the lipids of the skin and mucous membranes, where it contributes to barrier function, moisture retention, and tissue flexibility. The lipid profile of sea buckthorn pulp oil resembles the composition of human skin lipids more closely than most plant oils, making it unusually compatible with the skin's own lipid systems.

A study in Skin Pharmacology and Applied Skin Physiology (2003) identified that palmitoleic acid isomers found in human skin sebum are effective against gram-positive bacteria, documenting an antimicrobial function of this fatty acid in the skin lipid system.

Overall evidence strength: Topical and skin-related evidence is largely based on biochemical composition studies and limited cell/animal work. No controlled human interventional trials using purified palmitoleic acid as a topical agent were identified in the peer-reviewed sources retrieved.

6. Body Systems Associated with Palmitoleic Acid

Based on the body of research, the large number of publications linking this metabolite to a broad range of physiological functions suggests that any research program seeking to better understand metabolic, liver, cardiovascular, gastrointestinal, and oncological health may benefit from quantitative analysis of palmitoleic acid.

• Metabolic system: Regulation of glucose homeostasis, insulin sensitivity, and de novo lipogenesis via SCD1 and AMPK pathways. Acts as a lipokine communicating between adipose tissue and liver, muscle, and pancreas.
• Cardiovascular system: Epidemiological associations with triglyceride and LDL modulation, HDL elevation, and reduced incident diabetes. The trans-palmitoleate isomer from dairy fat has been associated with reduced metabolic cardiovascular risk in large cohort studies.
• Hepatic system: Evidence from animal models for suppression of NF-κB-mediated inflammation and modulation of hepatic steatosis; complex role in NAFLD where hepatic fat may be increased but hepatic inflammation is suppressed.
• Pancreas: Cell culture and animal evidence for protection of pancreatic beta cells against lipotoxicity and glucotoxicity, and promotion of beta-cell proliferation at normal glucose concentrations.
• Immune system: Demonstrated capacity to suppress LPS-induced macrophage inflammatory responses and inhibit NF-κB activation in multiple cell types. Palmitoleic acid's improvement of insulin tolerance was dependent on myeloid PPAR-γ, while its anti-inflammatory actions were preserved in cells deficient in PPAR-γ, overlapping with increased M2a macrophage polarization.
• Skin and mucosal membranes: Natural constituent of sebum and skin lipids; studied for barrier function support and antimicrobial properties.
• Lacrimal glands / ocular: Animal evidence for restoration of tear secretion through suppression of inflammatory cytokines in lacrimal tissue when palmitoleate is administered orally.

7. Dosage Forms and Reported Dosages

No official therapeutic dose has been established for palmitoleic acid by any regulatory or pharmacopeial authority. The following dosages have been reported in peer-reviewed studies:

• Animal (oral, mice): 300 mg/kg of palmitoleic acid administered daily for 4 weeks in KK-Ay diabetic mice.
• Human (purified capsule, retracted trial): Adults with dyslipidemia and mild systemic inflammation were randomly allocated to receive either 220.5 mg of cis-palmitoleic acid (n=30) or an identical capsule placebo, with results measured at 30 days. This trial was subsequently retracted (see below).
• Human (marine-source capsules, RCT, n=123): Participants consumed 500 mg/day or 1,000 mg/day of marine-source palmitoleic acid or placebo for 12 weeks.
• Ongoing RCT (protocol published): An 8-week clinical trial recruiting adults aged 18–70 years with BMI 25–40 kg/m², HOMA-IR above 2.5, HbA1c between 5.6–6.5, or impaired fasting plasma glucose (>99, ≤126 mg/dL).

Given the retraction of the most widely cited purified-palmitoleic acid human trial and the null results of the subsequent 12-week RCT at 500–1,000 mg/day, further study is needed to elucidate mechanisms and establish appropriate human doses.

8. Safety Considerations and Interactions

Retraction of Key Clinical Trial

A critical integrity issue affects the human RCT literature. A journal retracted the 2014 report of a clinical trial of palmitoleic acid as a supplement after beginning to suspect that the data were not reliable. The study, "Purified palmitoleic acid for the reduction of high-sensitivity C-reactive protein and serum lipids," was published in the Journal of Clinical Lipidology. The editor-in-chief, when asked whether the retraction notice suggesting results were "not consistent with known variability" indicated concern that data were not experimentally derived, confirmed: "That's correct." Any claims about efficacy based solely on this retracted study should be treated with caution.

The Cis–Trans Isomer Distinction

Palmitoleic acid has cis and trans structural isomers, which differ in their food intake route and metabolism in humans. Research should be evaluated with attention to which isomer was studied, as their sources, metabolic fates, and potential effects differ substantially. The cis isoform is endogenously produced and found in plant/fish sources; the trans isoform is primarily derived from dairy and ruminant fats.

Confounding by SCD1 Activity and Obesity

Human studies report elevated blood levels of palmitoleic acid in people with obesity and metabolic syndrome. These findings might be a reflection of the level or activity of stearoyl-CoA desaturase-1, which synthesizes palmitoleate and is enhanced in liver and adipose tissue of obese patients. This creates a significant interpretive challenge: elevated endogenous palmitoleate may indicate metabolic dysfunction rather than a protective state, complicating inference from observational data.

Contamination of Supplement Sources with Palmitic Acid

The issue of co-occurring palmitic acid in natural sources is methodologically important: pure (>90%) palmitoleic acid with <0.3% palmitic acid was specifically developed for research because palmitic acid is noted to mask the beneficial effects of palmitoleic acid. Most naturally-derived supplements (from macadamia oil, sea buckthorn, or fish oil) contain significant proportions of other fatty acids alongside palmitoleate, which complicates the attribution of any observed effect.

Lack of Long-Term Safety Data

Despite the beneficial effects observed in cell culture and in animal studies, there are insufficient human intervention studies to fully understand the physiological effects of palmitoleic acid. More human-based research is needed to identify whether palmitoleic acid meets the promising therapeutic potential suggested by the preclinical research.

Potential Interaction with Lipid-Altering Medications

Because palmitoleic acid has shown lipid-modifying activity in preclinical and limited human studies (triglyceride lowering, LDL lowering, HDL raising), and because the ongoing human trial protocol excludes participants taking lipid-modifying supplements such as fish oil, macadamia oil, cod liver oil, krill oil, flaxseed, and sea buckthorn oil within 3 months of participation, additive or interactive effects with lipid-altering pharmaceutical drugs are a theoretical concern, though specific human interaction data are not yet available in the peer-reviewed sources retrieved.

Inconsistency Between Animal and Human Data

In animals, an improved lipid profile and increased insulin sensitivity are explained through increased transcriptional activity, improved insulin signaling, and modulation of enzymes and cytokines. The rationale of inconsistencies observed between animals and humans is unknown. Due to the complicated interaction between diet and endogenous synthesis of palmitoleic acid, the hormone-like effects of palmitoleic acid were questioned by human studies.

References

• Frigolet ME, Gutiérrez-Aguilar R. "The Role of the Novel Lipokine Palmitoleic Acid in Health and Disease." Advances in Nutrition, 2017. PMC5227969
• NIH/PubChem. Palmitoleic Acid — CID 445638. National Library of Medicine.
• Protocol for a randomized placebo-controlled clinical trial using pure palmitoleic acid to ameliorate insulin resistance and lipogenesis in overweight and obese subjects with prediabetes. PMC10835623
• Pinnick KE et al. "The Importance of Palmitoleic Acid to Adipocyte Insulin Resistance and Whole-Body Insulin Sensitivity in Type 1 Diabetes." PMC3537110
• Yang ZH et al. "Chronic administration of palmitoleic acid reduces insulin resistance and hepatic lipid accumulation in KK-Ay Mice with genetic type 2 diabetes." PMC3155149
• Mozaffarian D et al. "Circulating palmitoleic acid and risk of metabolic abnormalities and new-onset diabetes." PMC2980960
• Stefan N et al. "Circulating palmitoleic acid is an independent determinant of insulin sensitivity, beta cell function and glucose tolerance in non-diabetic individuals." Diabetologia, 2019.
• Mozaffarian D et al. "trans-Palmitoleic acid, other dairy fat biomarkers, and incident diabetes: the Multi-Ethnic Study of Atherosclerosis (MESA)." PMC3607658
• Mozaffarian D et al. "Trans-Palmitoleic Acid, Metabolic Risk Factors, and New-Onset Diabetes in US Adults." PMC3056495
• Souza CO et al. "Is Palmitoleic Acid a Plausible Nonpharmacological Strategy to Prevent or Control Chronic Metabolic and Inflammatory Disorders?" PubMed 28980402
• Bernardi A et al. "Implications of Palmitoleic Acid (Palmitoleate) On Glucose Homeostasis, Insulin Resistance and Diabetes." PubMed 26648072
• Yang ZH et al. "Palmitoleate Induces Hepatic Steatosis but Suppresses Liver Inflammatory Response in Mice." PMC3387145
• Pimentel GD et al. "Palmitoleic acid reduces high fat diet-induced liver inflammation by promoting PPAR-γ-independent M2a polarization of myeloid cells." PMC7487782
• Souza CO et al. "Palmitoleic Acid (N-7) Attenuates the Immunometabolic Disturbances Caused by a High-Fat Diet Independently of PPARα." PMC4131426
• "Palmitoleate protects against lipopolysaccharide-induced inflammation and inflammasome activity." PMC11585775
• "Determination of Major Endogenous FAHFAs in Healthy Human Circulation." PMC7766943
• "Restoration of Tear Secretion in a Murine Dry Eye Model by Oral Administration of Palmitoleic Acid." PMC5409703
• "The Distinct Effects of Palmitic and Oleic Acid on Pancreatic Beta Cell Function." PMC6348268
• Retraction notice: Bernstein AM, Roizen MF, Martinez L. "Purified palmitoleic acid for the reduction of high-sensitivity C-reactive protein and serum lipids." J Clin Lipidol 2021;15(3):522. PubMed 34144766
• Retraction Watch. "Palmitoleic acid paper pulled for data concerns." April 2021.
• "Effects of a Palmitoleic Acid Concentrated Oil on C-Reactive Protein Levels in Adults: A Randomized Double-Blind Placebo Controlled Clinical Trial." Journal of Nutrition, 2025.
• "Therapeutic potential of palmitoleic acid in non-alcoholic fatty liver disease: Targeting ferroptosis and lipid metabolism disorders." PubMed 39243559
• "A review of biological functions, health benefits, and possible de novo biosynthetic pathway of palmitoleic acid in macadamia nuts." ScienceDirect.
• Tremblay F et al. "Fatty Acid Composition of Developing Sea Buckthorn Berry and the Transcriptome of the Mature Seed." PLOS ONE, 2012.
• "What Are n-7 Fatty Acids and Are There Health Benefits Associated with Them?" Journal of the Academy of Nutrition and Dietetics, 2015.
• LIPID MAPS Structure Database. Palmitoleic acid entry. LMFA01030056.
• Wikipedia. Palmitoleic acid. (For chemical/structural reference only.)